Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

Published Date: 18 Mar 2024

In a full day of meetings, the FDA advisory panel will assess the evidence for cilta-cel and ide-cel.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TULSA Is Effective in Long-Term Prostate Cancer Control.

2.

Five new papers highlight cancer inequities, challenges and opportunities in South Asia

3.

Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds

4.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot